LLY

765.61

+0.24%↑

JNJ

175.55

-0.76%↓

ABBV

220.25

-0.19%↓

UNH

340.14

-0.01%↓

AZN

76.65

-1.34%↓

LLY

765.61

+0.24%↑

JNJ

175.55

-0.76%↓

ABBV

220.25

-0.19%↓

UNH

340.14

-0.01%↓

AZN

76.65

-1.34%↓

LLY

765.61

+0.24%↑

JNJ

175.55

-0.76%↓

ABBV

220.25

-0.19%↓

UNH

340.14

-0.01%↓

AZN

76.65

-1.34%↓

LLY

765.61

+0.24%↑

JNJ

175.55

-0.76%↓

ABBV

220.25

-0.19%↓

UNH

340.14

-0.01%↓

AZN

76.65

-1.34%↓

LLY

765.61

+0.24%↑

JNJ

175.55

-0.76%↓

ABBV

220.25

-0.19%↓

UNH

340.14

-0.01%↓

AZN

76.65

-1.34%↓

Strona główna・Stock List・Codexis Inc

Codexis Inc

Open

SectorHealthcare

2.45 0.82

Buy Sell

Overview

Share price change

24h

Current

Min

2.31

Max

2.49

Key metrics
By Trading Economics
Income	7.4M -13M
Sales	7.8M 15M
EPS	-0.16
Profit margin	-86.587
Employees	188
EBITDA	7.6M -13M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+154.22% upside

Dividends
By Dow Jones
Next Earnings	30 paź 2025

Market Stats
By TradingEconomics
Market Cap	-12M 220M
Previous open	1.63
Previous close	2.45

News Sentiment

By Acuity

50%

167 / 371 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

2.25 / 2.53 Support & Resistance

Codexis Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

17 wrz 2025, 23:01 UTC

Acquisitions, Mergers, Takeovers

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17 wrz 2025, 22:48 UTC

Acquisitions, Mergers, Takeovers

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17 wrz 2025, 21:59 UTC

Earnings

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17 wrz 2025, 23:44 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

17 wrz 2025, 23:39 UTC

Market Talk

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17 wrz 2025, 22:20 UTC

Acquisitions, Mergers, Takeovers

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17 wrz 2025, 22:20 UTC

Acquisitions, Mergers, Takeovers

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17 wrz 2025, 22:20 UTC

Acquisitions, Mergers, Takeovers

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17 wrz 2025, 22:19 UTC

Acquisitions, Mergers, Takeovers

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17 wrz 2025, 22:18 UTC

Acquisitions, Mergers, Takeovers

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17 wrz 2025, 21:00 UTC

Earnings

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17 wrz 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

17 wrz 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 wrz 2025, 19:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 wrz 2025, 19:59 UTC

Market Talk

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17 wrz 2025, 19:07 UTC

Market Talk

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17 wrz 2025, 18:43 UTC

Market Talk

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17 wrz 2025, 18:38 UTC

Market Talk

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17 wrz 2025, 18:20 UTC

Market Talk

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17 wrz 2025, 18:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 wrz 2025, 18:18 UTC

Market Talk

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17 wrz 2025, 18:14 UTC

Market Talk

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17 wrz 2025, 17:59 UTC

Market Talk

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17 wrz 2025, 17:15 UTC

Acquisitions, Mergers, Takeovers

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17 wrz 2025, 17:06 UTC

Acquisitions, Mergers, Takeovers

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17 wrz 2025, 16:51 UTC

Earnings

Correct: Exor 1H Net Loss -EUR624M

17 wrz 2025, 16:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 wrz 2025, 16:34 UTC

Market Talk

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17 wrz 2025, 16:25 UTC

Earnings

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17 wrz 2025, 16:23 UTC

Earnings

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Peer Comparison

Price change

Codexis Inc Forecast

Price Target

By TipRanks

154.22% upside

12 Months Forecast

Average 6.33 USD 154.22%

High 11 USD

Low 3 USD

Based on 5 Wall Street analysts offering 12 month price targets forCodexis Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Codexis Inc - Dist in the past 3 months.

Technical Score

By Trading Central

2.25 / 2.53Support & Resistance

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

167 / 371 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Codexis Inc

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, the company is currently developing its proprietary ECO Synthesis(tm) manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.